Eliquis 2.5 mg film-coated tablets clinical trials
6 indexed studies · 0 currently recruiting
- AuthorisedPhase II and Phase III (Integrated)
Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms
This study compares new blood thinners (apixaban/Eliquis, rivaroxaban/Xarelto) with aspirin to see which best prevents blood clots in people with certain bone marrow conditions (myeloproliferative neoplasms) like Polycythemia Vera. It also looks at side effects, like bleeding.
For: Philadelphia-negative myeloproliferative neoplasms are frequent and chronic myeloid malignancies including Polycythemia Vera (PV) · essential thrombocythemia (ET) · Primary Myelofibrosis (PMF) and Prefibrotic myelofibrosis (PreMF).France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Open-Label, Active-Control Study of REGN9933, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism after Elective, Unilateral, Total Knee Arthroplasty
This study is testing a new medicine called REGN9933 to see if it can prevent blood clots after knee replacement surgery. Blood clots can be serious, so finding good ways to prevent them is important. We're comparing REGN9933 to other common clot-preventing medicines.
For: Thromboembolic diseaseLithuania · Latvia · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(19767 OCEANIC-AF) A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke
This study is testing a new medication called asundexian against a standard treatment (apixaban) to see how well it prevents strokes or serious blood clots in people with atrial fibrillation, a type of irregular heartbeat. It's also looking at how safe the new drug is.
For: Prevention of stroke or systemic embolism in atrial fibrillationFinland · Norway · Denmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A single dose of apixaban for the prevention of thrombotic events in the context of long-distance flights (DANCE FLIGHT)
This study looks at whether a single dose of a medicine called apixaban (Eliquis) can stop blood clots in the legs of people taking long flights. It aims to see if it's a safe and effective way to prevent these clots.
For: Symptomatic leg vein thrombosisGermany - AuthorisedTherapeutic use (Phase IV)
Anticoagulant medicines for Balloon Pulmonary Angioplasty
This study looks at how safe different blood-thinning medicines are during a procedure called Balloon Pulmonary Angioplasty (BPA). It focuses on patients with specific lung conditions to see if these medicines cause issues like bleeding or lung problems.
For: Chronic Thromboembolic Pulmonary Hypertension (CTEPH) · Chronic Thromboembolic Disease (CTED) without Pulmonary HypertensionNetherlands - AuthorisedTherapeutic confirmatory (Phase III)
MidregiOnal proatrial natriuretic peptide to guide SEcondary Stroke prevention: The MOSES-study. An international, multicentre, randomised-controlled, two-arm, assessor-blinded trial.
This study, called MOSES, is looking at how best to prevent another stroke in people who have recently had one. It's testing if a specific blood test, together with different blood-thinning medicines, can help doctors choose the best treatment to stop future strokes.
For: Acute ischemic strokeGreece · Spain